Skip to main content
HALO logo

HALO · Halozyme Therapeutics, Inc.

Track HALO — free
Market Cap
$12.37B
Shares
113.50M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Helen Torley $23,166,223
Nicole LaBrosse $4,578,814
Mark Snyder $4,531,568
Cortney Caudill $3,202,906
Michael J. LaBarre $2,053,642
Fiscal 2024
Executive Total
Helen Torley $12,741,421
Mark Snyder $5,394,865
Nicole LaBrosse $4,218,276
Michael J. LaBarre $3,038,441
Fiscal 2023
Executive Total
Helen Torley $11,820,858
Nicole LaBrosse $3,849,419
Mark Snyder $3,612,927
Michael J. LaBarre $3,243,941
Fiscal 2022
Executive Total
Helen Torley $9,696,978
Mark Snyder $3,740,202
Nicole LaBrosse $2,683,103

Executive changes

Person Change Filed
Dannielle Appelhans Appointed 2026-08-18
Darren Snellgrove Appointed 2026-04-30
Key facts CIK 1159036 CUSIP 40637H109 13F (30d) 407 filings 386 filers Visit website Investor relations